Sharyn D. Baker, PharmD, PhD
Sharyn D. Baker, PharmD, PhD

Sharyn D. Baker, PharmD, PhD

Associate Member, St. Jude Faculty

  • Director, Pharmacokinetics Shared Resource

Departments

Education

BA – Pacific Lutheran University, Tacoma, Washington (1986)
PharmD – University of California at San Francisco (1991)
PhD – Erasmus University, Rotterdam, the Netherlands (2004)

Research Interests

  • Developmental therapeutics of childhood acute myeloid leukemia
  • Clinical pharmacology of tyrosine kinase inhibitors
  • Pharmacokinetic variability of anticancer agents

Selected Publications

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick SJ, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, and Baker SD. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood 122:3607-15, 2013.

Xie C, Drenberg D, Edwards H, Chen W, Inaba H, Xu X, Buck S, Taub JW, Baker SD, Ge Y. Panobinosat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK2, and RAD51. PLoS One 8:e79106, 2013. PMCID: PMC3823972.

Baker SD , Zimmerman EI, Wang Y-D, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen S, Enemark EJ, Rubnitz JE, Shurtleff S, Mullighan CG, Inaba H. Emergence of FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive AML.Clin Cancer Res 19:5758-68, 2013.

Navid F, Christensen R, Inaba H, Li L, Chen Z, Cai X, Regel J, Baker SD. Alternative Formulations of Sorafenib for Use in Children. Pediatr Blood Cancer 60:1642-6, 2013. PMCID: PMC3800690.

Furmanski B, Hu S, Fujita K, Li L, Gibson AA, Janke L, Williams RT, Schuetz JD, Sparreboom A,Baker SD. Contribution of Abcc4-mediated gastric transport to the absorption and efficacy of dasatinib. Clin Cancer Res 19:4359-70, 2013. PMCID: PMC3752901.

Broniscer A, Baker SD, Wetmore C, Panandiker AS, Huang J, Davidoff AM, Onar-Thomas A, Panetta JC, Chin TK, Merchant TE, Baker JN, Kaste SC, Gajjar A, Stewart CF. Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Clin Cancer Res 19:3050-8, 2013. PMCID: PMC3685168.

Zimmerman EI, Hu S, Roberts JL, Li L, Sparreboom A, Baker, SD. Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide. Clinical Cancer Research19:1458-66, 2013. PMCID: PMC3602278.

Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, Davidoff AM, Spunt SL, Furman WL, McGregor LM, Hu S, Panetta JC, Turner D, Fofana D, Reddick WE, Leung W, Santana VM. Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors. Clinical Cancer Res 19:236-46, 2013. PMCID: PMC3537913.

Zimmerman EI, Roberts JL, Li L, Finkelstein D, Gibson A, Chaudhry AS, Schuetz EG, Rubnitz JE, Inaba H, and Baker SD. Ontogeny and sorafenib metabolism. Clin Cancer Res. 18:5788-95, 2012. PMCID: PMC3490489.

Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer107:1100-6, 2012.

de Graan AJ, Lancaster C, Obaidat A, Hagenbuch B, Elens L, FribergL , de Bruijn P, Hu S, Gibson A, Bruun G, Corydon T, Mikkelsen T, Walker A, Du G, Loos W, van Schaik R, Baker SD, Mathijssen R, Sparreboom A. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 18: 4433-4440, 2012. PMCID: PMC3464009.

Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, Bowman WP, Christensen R, Onciu M, Shurtleff SA, Pounds SB, Pui C-H, Ribero RC, Campana D, Baker SD. Phase I, Pharmacokinetic, and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination with Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. J Clin Oncol 29:3293-3300, 2011. PMCID: PMC3158600.

Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, Yang S, Pounds S, Calabrese C, Rehg JE, Campana D, Rubnitz J, Baker SD. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 103:893-905, 2011.

Franke RM, Lancaster CS, Peer CJ, Gibson AA, Kosloske AM, Orwick SJ, Mathijssen RH, Figg WD,Baker SD, Sparreboom A. Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism.Clin Pharmacol Ther Mar 30, 2011.

Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, Sue L. Heatley SL, Holmfeldt L, Collins-Underwood JR, Ma J, Buetow KH, Pui C-H, Baker SD, Brindle PK, Downing JR. CREBBP mutations in relapsed acute lymphoblastic leukemia. Nature 471:235-9, 2011. PMCID: PMC3076610.

Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, Campana D, Pui C-H, Downing JR, Rubnitz JE, Ribeiro RC. Identification of predictive markers of cytarabine response in acute myeloid leukemia by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 12:327-39, 2011. PMCID: PMC3139433.

Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat127:153-62, 2011. (PMCID: PMC3111459)

Smith BD, Jones RJ, Cho E, Kowalski J, Karp JE, Gore SD, Vala M, Meade B, Baker SD, Zhao M, Piantadosi S, Zhang Z, Blumenthal G, Warlick ED, Brodsky RA, Murgo A, Rudek MA, Matsui WH. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res 35:87-94, 2011. PMCID: PMC3033102.

Pratz K, Cho E, Levis JM, Karp JE, Gore SD, McDevitt M, Stine A, Zhao M, Carducci MA, Wright JJ,Baker SD, Rudek MA, Smith BD. A pharmacodynamic study of sorafenib in patients with relapsed and refractory leukemias. Leukemia 24:1437-44, 2010. PMCID: PMC2921005.

Li L, Zhao M, Navid F, Pratz K, Smith BD, Rudek MA, Baker SD. Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:3033-8, 2010. PMCID: PMC2956857.

Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer. J Clin Oncol 28:4562-7, 2010. PMCID: PMC2974340.

van Erp N, Baker SD, Zandvliet A, Ploeger B, Hollander M, Chen Z, Hartigh J, Konig-Quartel J, Guchelaar, HJ, Hans G. Increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol 67:695-703, 2011. PMCID: PMC3043256.

Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs 29:1057-65, 2011. PMCID: PMC3110647.

Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 27:4986-93, 2009. PMCID: PMC2799055.

Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res 15:6241-9, 2009. PMCID: PMC2845396.

Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 15:6062-9, 2009. PMCID: PMC2774722.

Call SK, Kasow KA, Barfield R, Madden R, Leung W, Horwitz E, Woodard P, Panetta JC, Baker S, Handgretinger R, Rodman J, Hale GA. Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant 15:274-8, 2009.

Baker SD, Hu S. Pharmacokinetic considerations for new targeted therapies. Clin Pharmacol Ther 85:208-11, 2009. PMCID: PMC2628961.

Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85:155-63, 2009.

Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower R. Phase I study of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, in adult patients with solid tumors. J Clin Oncol 26:5504-10, 2008.

Franke RM, Baker SD, Mathijssen RH, Schuetz E, Sparreboom A. Influence of Solute Carriers on the pharmacokinetics of CYP3A4 Probes. Clin Pharmacol Ther 84:704-9, 2008.

Minkin P, Zhao M, Chen Z, Ouwerkerk J, Gelderblom H, Baker SD. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry (LC/MS/MS).J Chromatogr B Analyt Technol Biomed Life Sci 874:84-8, 2008. PMCID: PMC2612784.

Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Heather J, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo D. Pharmacodynamic-guided modified continuous reassessment method (mCRM) –based, dose finding study of rapamycin in adult patients with solid tumors. J Clin Oncol 26:4172-9, 2008. PMCID: PMC 2654371.

Navid F, Christensen R, Minkin P, Stewart C, Furman WL, Baker SD. Stability of Sunitinib in Oral Suspension. Ann Pharmacother 42:962-6, 2008. (PMCID: N/A)

Hooker AC, ten Tije AJ, Carducci MA, Weber J, Garrett-Mayer, Gelderblom H, McGuire WP, Verweij J, Karlsson MO, Baker SD. Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements. Clin Pharmacol Ther 84:111-8, 2008. PMCID: PMC3092481.

Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Priet R, Collins C, Fleisher M, Heller G, Baker SD, Scher HI. A Phase II Trial of Docetaxel with Rapid Androgen Cycling as a Treatment for Patients with Prostate Cancer. J Clin Oncol 26:2959-65, 2008. PMCID: PMC3051836.

Hu S, Niu H, Minkin P, Orwick S, Shimada A, Inaba H, Dahl GVH, Rubnitz J, Baker SD. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther 7:1110-20, 2008.

Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD. Sparreboom A. Interaction of Imatinib with Human Organic Ion Carriers. Clin Cancer Res 14:3141-8, 2008.

Smith NF, Baker SD, Harris JW, Figg WD, Sparreboom A. Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. Br J Cancer 98:1630-2, 2008. PMCID: PMC2391127.

Li J , Jameson MB, Baguley BC, Pili R, Baker SD. Population pharmacokinetic-pharmacodynamic (PK-PD) model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in cancer patients. Clin Cancer Res 14:2102-10, 2008.

Gregorc V, Hidalgo M, Spreafico A, Cusatis G, Ludovini V, Ingersoll RG, Marsh S, Steinberg SM, Viganò MG, Ghio D, Villa E, Sparreboom A, Baker SD. Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib. Clin Pharmacol Ther 83:477-84, 2008.

Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 61:423-33, 2008.

Jimeno A, Messersmith WA, Lee CK, Ma WW, Laheru D, Donehower RC, Baker SD, Hidalgo M. Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. Ann Oncol 19:374-9, 2008. 

Show More

Britten CD, Rowinsky EK, Baker SD, LeMaistre, Weiss GR, Smith L, Stephenson J, Rothenberg M, Smetzer L, Collins W, Von Hoff DD, Eckhardt SG. A phase I and pharmacokinetic study of the rhodacyanine dye analog MKT 077. Clin Cancer Res 6:42-49, 2000.

Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor S-P, Thomas S, Sartorius SE, Donehower RC, Grochow LB, Spector T, Hohneker J, Rowinsky E. Phase I and pharmacologic study of oral 5-fluorouracil (5-FU) on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase (DPD) inactivator eniluracil. J Clin Oncol 18:915-926, 2000.

Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I trials. J Clin Oncol 18:2459-2467, 2000.

Britten CD, Baker SD, Denis LJ, Johnson T, Drengler R, Siu L, Caton J, Aylesworth C, Smith L, Von Hoff DD, Duchin K, Rowinsky E. Oral paclitaxel and concurrent cyclosporin A: dose-escalation and feasibility study. Clin Cancer Res 6:3459-3468, 2000.

Eckhardt SG, Baker SD, Weiss GR, Kraynak M, Britten C, Siu L, MacDonald JR, Smith S, De Moor C, Moczygemba J, Von Hoff DD, Rowinsky EK. A phase I and pharmacokinetic (PK) study of the novel mushroom-derived cytotoxin, MGI 114, in patients with advanced cancer. J Clin Oncol 18:4086-4097, 2000.

Fleming GF, Roth BJ, Baker SD, Sutton GP, Thigpen JT, Look KY, Muggia FM, Fracasso PM, McGuire III WP. Phase I Trial of paclitaxel and etoposide in patients with recurrent ovarian carcinoma: a report on Gynecologic Oncology Group (GOG) protocol # 9203. Am J Clin Oncol 23;(6):609-13, 2000.

Giles FJ, Cortes JE, Baker SD, Thomas DA, O’Brian S, Smith TL, Beran M, Bivins C, Jolivet J, Kantarjian HM. Troxacitabine (BCH-4556), A novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 19:762-771, 2001.

Gilbert J, Baker SD, Bowling MK, Louise G, Figg D, Zabelina Y, Donehower RC,  Carducci MA. A Phase I dose escalation, oral bioavailability, and feasibility study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292-2300, 2001.

Bradley MO, Swindell CS, Anthony FH, Witman PA., Devanesan P, Webb NL, Baker SD, Wolff SD, Donehower RC. Tumor targeting by conjugation of DHA to paclitaxel. J Controlled Release 74:233-236, 2001.

Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S, Chander MC, Baker SD, He L, Horwitz SB, Swindell CS. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7:3229-3238, 2001.

Belanger K, Moore M, Baker SD, Dionne J, Maclean M, Jolivet J, Siu L, Soulieres D, Wainman N, Seymour L. Phase I and pharmacokinetic study of a novel L-nucleoside analog troxacitabine, given as a 30 minute infusion every 21 days. J Clin Oncol 20:2567-74, 2002.

Sparreboom A, Zhao M, Brahmer JR, Verweij J, Baker SD. Determination of the docetaxel vehicle, polysorbate 80, in patient samples by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 773:183-190, 2002.

Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, Paoletti P, Calvert AH, Allen RH. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545-552, 2002

De Bono JS, Stephenson Jr J, Baker SD, Hidalgo M, Patnaik A, Hammond LA, Weiss G, Goetz A, Siu L, Simmons C, Jolivet J, Rowinsky EK. Troxacitabine, An L-Stereoisomeric Nucleoside, on a daily X 5 Schedule: A Phase I and Pharmacokinetic Study in Patients with Advanced Solid Malignancies. J Clin Oncol 20:96-109, 2002.

Giles FJ, Cortes JE, Garcia-Manero G, Baker SD, Miller CB, O’Brien SM, Thomas DA, Andreeff M, Beran M, Bivins C, Jolivet J, Kantarjian HM. Phase II Study of Troxatyl (BCH-4556), A Novel Dioxolane Nucleoside Analog, in Patients with Refractory Leukemia. J Clin Oncol 20:656-64, 2002

Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JHM, Grochow LB, Sparreboom A. Role of body-surface area in dosing of investigational anticancer agents in adults: 1991 – 2001. J Natl Cancer Inst 94:1883-1888, 2002.

Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire G, Swindell CS, Baker SD. Disposition of DHA-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin Cancer Res 9:151-159, 2003.

Aparicio A, Eads CA, Leong LA, Laird PW, Newman EM, Synold TW, Baker SD, Zhou M, Weber JS. Phase I trial of continuous infusion 5-Aza-2’-deoxycytidine (DAC). Cancer Chemother Pharmacol 51:231-239, 2003.

Gelderblom H, Baker SD, Zhao A, Verweij J, Sparreboom A. Distribution of paclitaxel in plasma and cerebrospinal fluid. Anti-Cancer Drugs 14:365-368, 2003.

Mathijssen RHJ, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A,  McLeod HL. Irinotecan disposition in relation to genetic polymorphisms in ABC transporters and drug-metabolizing enzymes. Clin Cancer Res 9:3246-3253, 2003.

Zhao M, He P, Rudek MA, Hidalgo M, Baker SD. A rapid and specific method for the determination of OSI 774 and its metabolite OSI 420 in human plasma by using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 793:413-420, 2003.

Wolff AC, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman PA, Webb NL, Baker SD. Phase I study of DHA-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9:3589-3597, 2003.

Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 74: 364-371, 2003.

Ten Tije AJ, Loos WJ, Verweij J, Baker SD, Dinh K, Figg WD, Sparreboom A. Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches. Clin Pharmacol Ther 74:509-10, 2003.

Govindan R, Read W, Faust J, Trinkaus K, Ma MK, Baker SD, McLeod HL, Perry MC. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.Oncology (Huntingt) 17(9 Suppl 8):27-31, 2003.

Zhao M, Zabelina Y, Rudek MA, Wolff AC, Baker SD. A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS. J Pharm Biomed Anal 33:725-733, 2003.

Baker SD, Zhao M, He P, Carducci MA, Verweij J. Simultaneous determination of docetaxel and the formulation vehicle polysorbate 80 in human plasma by LC/MS/MS. Analyt Biochem 324:276-842, 2004.

Rudek MA, Donehower RC, Statkevich P, Bara VK, Cutler DL, Baker SD. Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. Pharmacotherapy 24:16-25, 2004.

Baker SD, Zhao M, Lee C, Brahmer J, Carducci MA, Wolff A, Verweij J, Sparreboom A. Pharmacokinetics of docetaxel following weekly and every 21-day schedules using LC-MS-MS. Clin Cancer Res 10:1976-1983, 2004.

Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 40:1170-1178, 2004.

Engels F, ten Tije AJ, Baker SD, Lee CKK, Loos WJ, Vulto AG, Verweij J,  Sparreboom A. Effect of CYP3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75:448-454, 2004.

Rudek MA, Zabelina Y, Zhao M, Wolff AC, Baker SD. A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. Biomed Chromatog 18:282-72003, 2004.

ten Tije AJ, Loos WJ, Zhao M, Baker SD, Verweij J, Sparreboom A. Limited cerebrospinal fluid penetration of docetaxel. Anti-Cancer Drugs 15:715-718, 2004.

Acharya MA, Baker SD, Verweij J, Figg WD, Sparreboom A. Determination of fraction unbound docetaxel using micro-equilibrium dialysis. Anal Biochem 331:192-4, 2004.

Zhao M, Baker SD, Yan X, Zhao Y, Wright WW, Zirkin BR, Jarow JP. Simultaneous determination of steroid composition of human testicular fluid using liquid chromatography tandem mass spectrometry. Steroids 69:721-726, 2004.

Baker SD, van Schaik RHN, Rivory LP, ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MS, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10:8341-50, 2004.

Amador ML, Oppenheimer D, Perea S, Maitra A, Cusati G, Iacobuzio-Donahue C, Baker SD, Takimoto C, Forastiere A, Hidalgo M. Genetic Basis of Epidermal Growth Factor Receptor Inhibitors Pharmacological Actions. Cancer Res 64:9139-43, 2004.

Zhao M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker SD. Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 25:81-88, 2004.

Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A. Relation of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 77:43-53, 2005.

Dees EC, Baker SD, O’Reilly S, Rudek M, Aylesworth C, Byrd J, Grever M, Elza-Brown K, Carducci MA, Donehower RC. A phase I and pharmacologic study of short infusions of the protein kinase C inhibitor UCN-01 in patients with refractory solid tumors. Clin Cancer Res 11:664-71, 2005.

ten Tije AJ, Verweij J, Carducci MA, Rogers T, Pronk T, Verbruggen MP, Dawkins F, Baker SD. Prospective Evaluation of the Pharmacokinetics, CYP3A Phenotype, and Toxicity Profile of Docetaxel in the Elderly. J Clin Oncol 23:1070-7, 2005.

Zhao M, Rudek MA, He P, Smith BD, Baker SD. A rapid and sensitive method for determination of bryostatin 1 in human plasma by using LC/MS/MS. Anal Biochem 337:143-8, 2005.

Rudek MA, Hartke C, Zabelina Y, Zhao M, New P, Baker SD. A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection. J Pharm Biomed Anal 37:751-6, 2005.

Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study. Neuro-oncol 7:177-82, 2005.

Zhao M, Hartke C, He P, Jimeno A, Li J, Zabelina Y, Hidalgo M, Baker SD. A rapid and sensitive method for determination of gefitinib in plasma and tissue using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 819:73-80, 2005.

Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, Carducci MA, Baker SD. Pharmacokinetics of 5-azacitidine given with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23:3906-11, 2005.

Lepper EP, Baker SD, Permenter M, Ries N, van Schaik RHN, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RHJ, Verweij J, Figg WD, Sparreboom A. Impact of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 11:7398-404, 2005.

van Erp N, Baker SD, Zhao M, Guchelaar HJ, Sparreboom A, Gelderblom H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 11:7800-6, 2005.

Rudek MA, Zhao M, Smith NF, Robey RW, He P, Khan S, Hidalgo M, Jimeno A, Colevas D, Messersmith WA, Wolff AC, Baker SD. In vitro and in vivo metabolism of BPU, a novel oral tubulin-targeted agent. Clin Cancer Res 11:8503-11, 2005.

Rudek MA, Zhao M, He P, Zabelina Y, Messersmith WA, Wolff AC, Baker SD. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate BPU and its 5 metabolites in human plasma and urine for clinical pharmacology studies. J Chromatogr B Analyt Technol Biomed Life Sci 828:41-54, 2005.

Sweeney CJ, Takimoto CH, Latz JE, Baker SD, Murry D, Krull JH, Fife K, Battiato L, Cleverly A, Chaudhary AK, Chaudhuri T, Sandler A, Mita AC, Rowinsky EK. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clin Cancer Res 12:536-542, 2006.

Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Huso D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar S. Ductal access for prevention and therapy of mammary tumors.Cancer Res 66:638-645, 2006.

Mita AC, Sweeney CJ, Baker SD, Goetz A, Felton S, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Johnson RD, Rowinsky EK, Takimoto CH. A Phase I and pharmacokinetic study of pemetrexed administered intravenously every 3 weeks to advanced cancer patients with impaired renal function. J Clin Oncol 24:552-562, 2006.

Messersmith WA, Baker SD, Dinh K, Lassiter LK, Akdamar RA, Wright JJ, Donehower RC, Carducci MA, Armstrong DK. Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12:1270-1275, 2006.

Li J, Brahmer J, Messersmith W, Hidalgo M, Baker SD. Binding of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, to plasma proteins and blood cells: in vitro and clinical pharmacokinetic studies. Invest New Drugs 24:291-297, 2006 (July).

Lee CKK, Rowinsky EK, Li J, Gile F, Moore JJ, Chu E, Hidalgo M, Capparelli E, Jolivet J, Baker SD. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clin Cancer Res 12:2158-2165, 2006.

Rudek MA, Zhao M, He P, Messersmith WA, Baker SD. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies. J Pharm Biomed Anal 42:253-60, 2006.

Gilbert J, Dees EC, Carducci MA, Baker SD, Dees EC Donehower R. A Phase I study of the oral antimetabolite, CS-682, administered once daily for 5 days per week in patients with refractory solid tumor malignancies. Invest New Drugs 24:499-508, 2006.

Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas Caravelli J, Yeung JH, Kris M, Gomez J, Miller V, D’Andrea G, Scher HI, Norton L, Hudis C. Pharmacokinetics and toxicity of weekly docetaxel in the elderly. Clin Cancer Res 12:6100-5, 2006.

Gardner ER, , Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 80:192-201, 2006.

Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD, Zahurak M, Carducci MA. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. Am J Clin Oncol 29:395-8, 2006.

Li J, Karlsson MO, Brahmer J, Spitz A, Zhao M, Hidalgo M, Baker SD. CYP3A4-phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 98:1714-1723, 2006.

Cusatis, G, Gregorc, V, Li, J, Spreafico, A, Ingersoll, RG, Hidalgo, M, Verweij, J, Ludovini, V, Eugenio Vila, Sparreboom, A, Baker SD. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98:1739-1742, 2006.

Zhao M, Rudek MA, He P, Hafner FT, Radtke M, Wright JJ, Smith BD, Messersmith WA, Hidalgo M,Baker SD. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 846:1-7, 2007.

Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins C, Colevas AD, Donehower RC, Carducci MA, Wolff AC. Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. Eur J Cancer 43:78-86, 2007.

Zhao M, Rudek MA, Mnasakanyan A, Hartke C, Pili R, Baker SD. A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. J Pharm Biomed Anal 43:784-7, 2007.

Wang H, Huang H, Li H, Teotico DG, Sinz M, Baker SD, Staudinger J, Kalpana G, Redinbo MR, Sridhar M. Activated pxr is a target for ketoconazole and its analogs. Clin Cancer Res 13:2488-95, 2007.

Li J, Cusatis G, Robey R, Bates S, Sparreboom A, Hidalgo M, Baker SD. Identification of ABCG2 as a high-affinity efflux transporter of the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol Ther 6:432-8, 2007.

Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P-450 enzymes. Clin Cancer Res 13:3731-7, 2007.

Kato Y, Okollie B, Raman V, Vesuna F, Zhao M, Baker SD, Bhujwalla ZM, Artemov D. Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther 6:891-7, 2007.

Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD. Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese. J Clin Oncol 25:4707-13, 2007.

van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, Nortier JW, Guchelaar HJ,Baker SD, Sparreboom A. Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. Clin Cancer Res 13:7394-400, 2007.

Last update: December 2013